[HTML][HTML] Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
[HTML][HTML] Cardiovascular benefits from gliflozins: effects on endothelial function
T Salvatore, A Caturano, R Galiero, A Di Martino… - Biomedicines, 2021 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
[HTML][HTML] SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the …
L Ma, R Zou, W Shi, N Zhou, S Chen, H Zhou… - Theranostics, 2022 - ncbi.nlm.nih.gov
Background: Given the importance of microvascular injury in infarct formation and
expansion, development of therapeutic strategies for microvascular protection against …
expansion, development of therapeutic strategies for microvascular protection against …
[HTML][HTML] Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
AC Sposito, I Breder, AAS Soares… - Cardiovascular …, 2021 - Springer
Background The glucose-lowering independent effect of sodium glucose cotransporter-2
inhibitors (SGLT2i) on arterial wall function has not yet been clarified. This study aims to …
inhibitors (SGLT2i) on arterial wall function has not yet been clarified. This study aims to …
[HTML][HTML] Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies
AS Alshnbari, SA Millar, SE O'Sullivan, I Idris - Diabetes Therapy, 2020 - Springer
Introduction While the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2)
inhibitors on cardiovascular and renal outcomes are recognized, their direct effects on …
inhibitors on cardiovascular and renal outcomes are recognized, their direct effects on …
[HTML][HTML] Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of …
R Wei, W Wang, Q Pan, L Guo - Frontiers in Endocrinology, 2022 - frontiersin.org
Objective This systematic review and meta-analysis aimed to evaluate the effects of SGLT-2
inhibitors (SGLT-2i) on endothelial function and arteriosclerosis in diabetic patients …
inhibitors (SGLT-2i) on endothelial function and arteriosclerosis in diabetic patients …
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
N Katsiki, E Ferrannini - Journal of Diabetes and its Complications, 2020 - Elsevier
Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …
[HTML][HTML] Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure
Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors present a class of antidiabetic
drugs, which inhibit renal glucose reabsorption resulting in the elevation of urinary glucose …
drugs, which inhibit renal glucose reabsorption resulting in the elevation of urinary glucose …
[HTML][HTML] Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus
S Chen, Y Shen, YH Liu, Y Dai, ZM Wu… - Cardiovascular …, 2021 - Springer
Background We investigated whether glycemic control affects the relation between
endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus …
endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus …
Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation
Y Faridvand, H Kazemzadeh… - Clinical and …, 2022 - Wiley Online Library
Hyperglycaemia is a major cause of pathophysiological processes such as oxidative stress,
inflammation, and apoptosis in diabetes. Dapagliflozin (DAPA), a novel hypoglycaemic drug …
inflammation, and apoptosis in diabetes. Dapagliflozin (DAPA), a novel hypoglycaemic drug …